Report copyright - Q1 2019 Results - AstraZeneca · 3 Respiratory Sales growth of 9% in the quarter (14% at CER) to $1,283m, including: − A Symbicort sales decline of 8% (3% at CER) to $585m.US sales,
Please pass captcha verification before submit form